Project Details
Description
HM2023-43: A phase 2 trial of tafasitamab in combination with lenalidomide+rituximab in treatment-naive follicular lymphoma and marginal zone lymphoma
| Status | Active |
|---|---|
| Effective start/end date | 11/18/24 → 11/17/35 |
Funding
- INCYTE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.